Drug Profile
Research programme: cathepsin S inhibitors - sanofi-aventis/Celera Genomics
Alternative Names: Cathepsin S inhibitors research programme - Aventis/Celera GenomicsLatest Information Update: 08 Aug 2005
Price :
$50
*
At a glance
- Originator Celera Genomics Group
- Class
- Mechanism of Action Cathepsin S inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Atherosclerosis; Autoimmune disorders; Chronic obstructive pulmonary disease; Inflammation; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 27 Jul 2005 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 27 Jul 2005 Discontinued - Preclinical for Atherosclerosis in USA (PO)
- 27 Jul 2005 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)